PEPTONIC medical AB

Equities

PMED

SE0005962206

Biotechnology & Medical Research

End-of-day quote NORDIC GROWTH MARKET Other stock markets 06:00:00 2024-01-30 pm EST			5-day change	1st Jan Change
0.06 ^SEK	-.--%		-.--%	+3.45%

May. 31	Peptonic Medical Secures European Patent for Treatment of Vulvodynia	MT
May. 31	Peptonic Medical AB Grants Patent in Europe for Relief of Provoked Vulvodynia in Women, Product Ready for Launch	CI

PEPTONIC medical AB Reports Earnings Results for the First Quarter Ended March 31, 2024

May 07, 2024 at 03:05 am EDT

PEPTONIC medical AB (publ) reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported revenue was SEK 11.15 million compared to SEK 9.07 million a year ago. Net loss was SEK 10.66 million compared to SEK 8 million a year ago.

Latest news about PEPTONIC medical AB

Peptonic Medical Secures European Patent for Treatment of Vulvodynia	May. 31	MT
Peptonic Medical AB Grants Patent in Europe for Relief of Provoked Vulvodynia in Women, Product Ready for Launch	May. 31	CI
Peptonic Medical AB Announces Organizational Changes	May. 21	CI
Sweden’s Peptonic Medical Names New CFO	May. 15	MT
PEPTONIC medical AB Announces Chief Financial Officer Changes	May. 15	CI
PEPTONIC medical AB Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Peptonic Medical Plans SEK61 Million Shares, Warrants Issue	Apr. 17	MT
Peptonic Medical Secures US Patent for Vaginal Yeast Infections Treatment	Apr. 15	MT
Sweden’s Peptonic Medical Enters Benelux Distribution Deal for Women's Self-care Products	Apr. 02	MT
Peptonic Medical AB Strengthens Its Position in Europe Through an Exclusive Distribution Agreement for Vagivital and Vernivia in the Benelux Region	Apr. 02	CI
Peptonic Medical CFO to Depart in Mid-June	Mar. 29	MT
PEPTONIC medical AB Announces Resignation of Albert Lindgren as CFO	Mar. 28	CI
Farmasiet Extends Partnership with Peptonic Medical, Bringing VagVital's Product Portfolio to Norway	Jan. 17	CI
Peptonic Medical AB Announces Patented Apoteket Offering in 293 Apoteket Stores	Dec. 18	CI
PEPTONIC medical AB completed the acquisition of Pharmiva AB (OM : PHARM).	Nov. 20	CI
Peptonic Medical Gains on Deal with Al Fotune for VagiVital VS Pro Distribution in UAE	Nov. 13	MT
Peptonic Medical AB Signs Distribution Agreement with Al Fotune for United Arab Emirate	Nov. 13	CI
Peptonic Medical AB's Self-Test for Bacterial Vivinosis to Be Sold in over 220 Apoteket Stores	Nov. 08	CI
PEPTONIC medical AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-24	CI
Peptonic Medical Lands First Vaginal Self-test Order for Central American Market	23-10-19	MT
Peptonic Medical AB Receives First Order in Central America from Windsor Pharmaceuticals	23-10-19	CI
Peptonic Medical's Bacterial Vaginosis Self-test Kit to Start Selling at Walmart in US	23-10-10	MT
Pharmiva Accepts Peptonic Merger for Creation of Global Femtech Company	23-08-21	MT
PEPTONIC medical AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Peptonic Medical AB Appoints Albert Lindgren as Chief Financial Officer, Effective from October 21, 2023	23-08-01	CI

Chart PEPTONIC medical AB

Duration

Period

More charts

Company Profile

Peptonic Medical AB is a Sweden-based company active in the field of biotechnology. The Company develops estrogen-free pharmaceuticals for treatment of vaginal atrophy. The Company's main drug candidate is Vagitocin, an oxytocin-based pharmaceutical preparation for the treatment of vaginal atrophy and other menopause-related symptoms. The patented treatment is based on local, vaginal application of oxytocin to rejuvenate the vaginal mucosa. Vagitocin is to enter phase III clinical trials in Europe and the United States.

Sector

Biotechnology & Medical Research

Calendar

2024-08-12 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PEPTONIC MEDICAL AB	+3.45%	8.76M
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B

Bio Therapeutic Drugs